When analysing the prognostically relevant combinational subgroups based on both BRAF mutational status and MMR status, we observed significant differences in CRC-specific and overall survival according to SARIFA-status within the﻿ BRAFwt/pMMR, BRAFmut/pMMR, and BRAFmut/dMMR subgroups, but not the BRAFwt/dMMR subgroup (Supplementary Figures S4 and S5, Supplemental Digital Content 1, http://links.lww.com/PAS/C100). This evidence concerns the gene BRAF and colorectal carcinoma.